Adam D. Cutler - Mar 3, 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Role
Chief Financial Officer
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Adam D. Cutler
Stock symbol
MURA
Transactions as of
Mar 3, 2025
Transactions value $
$0
Form type
4
Date filed
3/5/2025, 04:47 PM
Previous filing
Nov 1, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Award $0 +35K +48.99% $0.00 106K Mar 3, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Award $0 +65K $0.00 65K Mar 3, 2025 Ordinary Shares 65K $3.43 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of ordinary shares issuable under 35,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2025, subject to the reporting person's continued service with the Issuer.
F2 Includes 59,144 unvested restricted stock units.
F3 This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer.